Synonym
Mexrenone; SC 25152; SC-25152; SC25152; ZK 32055; ZK-32055; ZK32055;
IUPAC/Chemical Name
methyl (7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-carboxylate
InChi Key
ADZYJDJNIBFOQE-RGKMBJPFSA-N
InChi Code
InChI=1S/C24H32O5/c1-22-8-4-15(25)12-14(22)13-16(21(27)28-3)20-17(22)5-9-23(2)18(20)6-10-24(23)11-7-19(26)29-24/h12,16-18,20H,4-11,13H2,1-3H3/t16-,17+,18+,20-,22+,23+,24-/m1/s1
SMILES Code
C[C@]12CCC(C=C1C[C@@H](C(OC)=O)[C@@H]3[C@@H]2CC[C@@]4(C)[C@H]3CC[C@@]45CCC(O5)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
400.51
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Preisig CL, Laakso JA, Mocek UM, Wang PT, Baez J, Byng G. Biotransformations of the cardiovascular drugs mexrenone and canrenone. J Nat Prod. 2003 Mar;66(3):350-6. PubMed PMID: 12662091.
2: Ménard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52. PubMed PMID: 15134800.
3: de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987 Feb;240(2):650-6. PubMed PMID: 2949071.
4: Fagart J, Seguin C, Pinon GM, Rafestin-Oblin ME. The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. Mol Pharmacol. 2005 May;67(5):1714-22. Epub 2005 Feb 16. PubMed PMID: 15716462.
5: Cutler GB Jr, Pita JC Jr, Rifka SM, Menard RH, Sauer MA, Loriaux DL. SC 25152: A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat prostate. J Clin Endocrinol Metab. 1978 Jul;47(1):171-5. PubMed PMID: 263288.
6: Sutanto W, de Kloet ER. ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43. PubMed PMID: 3193846.
